Welcome to the 503rd Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days.
The highlights of this week's edition are randomised controlled trials on tofacitinib in patients hospitalized with Covid-19 pneumonia & the effect of systemic hydrocortisone initiated 7 to 14 days after birth in ventilated preterm infants; systematic reviews and meta analyses on high flow nasal oxygen for acute type two respiratory failure & corticosteroids in ARDS; and observational studies on Covid-19 breakthrough infections in vaccinated health care workers & electrical rhythm degeneration in adults with out-of-hospital cardiac arrest according to the no-flow and bystander low-flow time.
There are also narrative reviews on ultrasound during cardiopulmonary resuscitation & coagulopathy in COVID-19; editorials on human albumin infusion strategy in liver cirrhosis & why improved PF ratio should not be our target when treating ARDS; and commentaries on SARS-CoV-2 variants & using updated PubMed; as well as correspondence on spike-antibody waning after second dose of BNT162b2 or ChAdOx1 & diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients.
If you only have time to read one review article this week, try this one on Long COVID.
Major Trial Results Livestreams
We have 3 major trial results livestreams to bring you over the next week. Tomorrow, Wednesday August 4th, the multiplatform anticoagulation in COVID-19 trial group present their results, followed on Thursday August 5th, by the RECOVERY-RS trial comparing CPAP vs HFNO vs standard care in hypoxic COVID-19 patients. Next week, on Tuesday 10th, we have the massive 11,000 patient BASICS trial from Brazil, comparing both saline with plasmalyte, and faster with slower fluid infusion rates. All three livestreams will be freely available on the Critical Care Reviews homepage.